In preclinical models, CSF-1R inhibition led to decreased tumor growth and invasion [78,81], although therapeutic efficacy varied depending on the glioma subtype [82], possibly depending on the heterogeneity of GAMM populations discovered through a recent single-cell RNA sequencing study [83]. The gene discussed is CSF1R; the disease is neoplasm.